文献速递乳腺乳腺X线

BI-RADS 4 类病变在重组对比增强乳腺摄影图像上无强化时能否降级

BIRADS 4 - Is it possible to downgrade lesions that do not enhance on recombinant contrast-enhanced mammography images?
PubMed 文献 · Eur J Radiol · 2023-08-23

该回顾性单中心研究纳入2017年1月至2022年11月因CEM分类为BI-RADS 4类而接受空心针活检的528例患者,分析病变形态并评估无强化病变降级BI-RADS类别的可能性。全组CEM阴性预测值为93.9%,肿块、非肿块和微钙化分别为100%、97.8%和87.9%;383个良性病变中230个无强化,60.1%的不必要空心针活检可被正确避免。结论认为CEM对肿块和非肿块形态病变检测恶性敏感性高,重组图像高阴性预测值提示无强化支持良性并可能降级BI-RADS类别。

要点

  • BI-RADS 4类病变中,CEM重组图像无强化者全组阴性预测值为93.9%。
  • 肿块形态病变无强化阴性预测值达100%,非肿块为97.8%,微钙化为87.9%。
  • 383个良性病变中230个无强化,60.1%的不必要空心针活检可被正确避免。

核心结论

  • CEM对肿块和非肿块形态的恶性病变检测敏感性高。
  • 重组图像高阴性预测值提示肿块和非肿块病变无强化支持良性,可能支持BI-RADS类别降级。

研究设计与样本

  • 回顾性单中心研究,纳入528例因CEM分类为BI-RADS 4类而接受空心针活检的患者,检查时间为2017年1月至2022年11月。
  • 复习患者电子记录和影像检查,将病变按形态分为肿块、非肿块和微钙化三类。
  • 计算全组及各形态类别的敏感度、特异度、阳性预测值和阴性预测值,并分析病变直径对结果的影响。

诊断标准与关键数值

  • 全组CEM阴性预测值为93.9%(95%CI 90.0-96.4)。
  • 肿块病变阴性预测值为100%(95%CI 94.5-100),非肿块病变为97.8%(95%CI 87.0-99.9),微钙化为87.9%(95%CI 80.3-93.0)。
  • 病变<20 mm的CEM敏感度为86.6%(95%CI 76.8-92.8),病变≥20 mm为94.6%(95%CI 86.0-98.2),<20 mm低于≥20 mm。

临床应用与阅片要点

  • 对BI-RADS 4类肿块或非肿块病变,CEM重组图像无强化时阴性预测值高(肿块100%、非肿块97.8%),可能支持良性判断并考虑降级BI-RADS类别。
  • 微钙化病变无强化的阴性预测值为87.9%,低于肿块和非肿块病变。
  • 病变<20 mm时CEM敏感度为86.6%,低于≥20 mm的94.6%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Analysis of the morphology of lesions classified into the BI-RADS 4 category and assessment of the possibility of downgrade the BI-RADS category in those that did not show enhancement on recombinant contrast-enhanced mammography (CEM) images.

METHOD: The retrospective, single-center study included 528 patients who underwent a core needle biopsy performed from January 2017 to November 2022 due to a breast lesion classified as BI-RADS 4 on CEM. Patients' electronic records and imaging examinations were reviewed. Individual lesions were classified into the morphological categories of mass, non-mass, and microcalcifications. Sensitivity, specificity, positive as well as negative predictive values were calculated for the whole group and individual morphological categories. The influence of the lesions' diameter on the results was analyzed.

RESULTS: CEM NPV for the whole group was 93.9% (±95% CI: 90.0-96.4), for mass lesions 100% (±95% CI: 94.5-100), for non-mass lesions 97.8% (±95% CI: 87.0-99.9) and 87.9% (±95% CI: 80.3-93.0) for microcalcifications. Given that 230 out of 383 benign lesions were not contrast-enhancing, 60.1% of unnecessary CNBs would have been correctly avoided. CEM sensitivity for lesions < 20 mm was lower than for lesions ≥ 20 mm and was respectively 86.6% (±95% CI: 76.8-92.8) vs 94.6% (±95% CI: 86.0-98.2), respectively.

CONCLUSION: CEM is characterized by high sensitivity in the detection of malignant lesions in the case of lesions with mass and non-mass morphology. The high NPV for recombinant images suggests that in the case of these lesions, the lack of enhancement supports the benign nature of the lesion and may lead to a downgrade of the BI-RADS category.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Grażyńska A, Niewiadomska A, Owczarek AJ, et al. BIRADS 4 - Is it possible to downgrade lesions that do not enhance on recombinant contrast-enhanced mammography images? Eur J Radiol. 2023. PMID: 37643559. doi:10.1016/j.ejrad.2023.111062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。